

2023 R&D Day

STRONG FOUNDATION POSITIONED FOR NEXT CHAPTER OF GROWTH



We are the **customer's first choice** through entire product life-cycle



Positioned in strong markets with innovative solutions across Nucleic Acid Production and Biologics Safety Testing



Comprehensive portfolio of products and services drives **stickiness across the Maravai ecosystem**



Targeting long-term high double-digit growth through **differentiated technologies and execution**



Investing in the next generation of Maravai to drive long-term sustainable growth

Built on a solid foundation for sustainable growth

Strong financial position

Innovative talent

Broad reach

Robust customer base

Leveraging key differentiators



Own the **front end of the funnel**



Be the **customers' first choice**



Leverage world-class **employee base of industry experts**




Deliver **industry-leading technology and IP**



Capitalize on entrepreneurial spirit with a focus on speed and agility


OPPORTUNITIES ABOUND IN STRONG MARKETS

Our solutions are well-positioned to capture the expanding pipeline of mRNA and cell & gene therapy applications



Nucleic acid products

- mRNA therapeutics in development expected to grow 4x from 2022-2027
- CleanCap® and small molecules included across the growing mRNA customer base
- Combining nucleic acid products and services to drive flywheel effect



Biologics safety testing

- Cygnus has set the gold standard in bioprocess impurity testing
- The FDA expects more than 200 INDs/year in Cell & Gene Therapy
 - Cygnus kits are used in all 17 approved CAR-T cell and gene therapy drugs

Strategic initiatives expected to drive double-digit organic growth

Leading innovator and supplier to mRNA producers	Innovation in oligonucleotides and capping analogs	Nucleic acid enzyme customization
Custom mRNA solutions and services to accelerate drug development	Expanding R&D capabilities	Biologics safety testing product and service expansion

COMPREHENSIVE STRATEGY TO CAPTURE OPPORTUNITY

Four-pillared growth strategy




Investing in innovation

- Customer-focused innovation to solve workflow challenges
- Advancing capabilities with industry-leading expertise

Optimizing and leveraging manufacturing footprint

- Catalyzing the customer journey across the lifecycle
- Bolstered manufacturing space to support later-stage mRNA development



Scaling commercial organization

- Establishing robust systems and processes
- Investing in automation and simplifying customer workflows

Inorganic growth opportunities

- Focused M&A driving long-term value creation
- Vertical supply chain integration
- International expansion



ATTRACTIVE LONG-TERM GROWTH OUTLOOK

Strong financial position



Driving future revenue growth targets through a combination of

- Leveraging established capabilities
- Innovation and strengthening key differentiators
- Inorganic tuck-in acquisitions



Targeting margin expansion through

- Combining robust cost control and operational excellence with world-class facility cost structure



Focused and intelligent capital allocation

- Continue value-enhancing and innovative acquisitions to improve synergistic capabilities

By 2028, we expect to deliver



Forward-looking statements

This document contains, and Maravai's officers and representatives may from time-to-time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this document which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravai's 2028 financial targets and expectations; expected innovations in our products and services, and opportunities for inorganic growth through M&A, constitute forward-looking statements and are identified by words like "outlook," "goal," "trend," "target," "believe," "expect," "see," "project," "may," "will," "should," "seek," "anticipate," or "could" and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, continued demand for our COVID-19 related products and services, which currently comprise a significant portion of our revenue, and the other risks and uncertainties described in greater detail in the "Risk Factors" section of our most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

Proven leadership team with significant life sciences experience



Carl Hull
Executive Chairman of the Board



Trey Martin
Chief Executive Officer



Kevin Herde
EVP, Chief Financial Officer



Pete Leddy, PhD
EVP, Chief Administrative Officer



Kate Broderick, PhD
Chief Innovation Officer



Becky Buzzeo
Chief Commercial Officer



Christine Dolan
Chief Operating Officer, Biologics Safety Testing



Drew Burch
EVP, Nucleic Acid Products



Chad Decker
VP and GM, Enzymes



Deb Barbara
VP, Strategy and Business Development

Maravai LifeSciences
10770 Wateridge Circle, Suite 200
San Diego, CA 92121
www.maravai.com

Deb Hart
Head of Investor Relations
Direct: 858-988-5917
Debra.hart@maravai.com